

CYTOGEN CORP  
Form 15-12G  
May 09, 2008

OMB APPROVAL  
OMB  
Number: 3235-0167  
Expires: November 30,  
2010  
Estimated average burden  
hours per response . . . . .  
1.50

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE  
SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS  
13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 000-14879

Cytogen Corporation

---

(Exact name of registrant as specified in its charter)

650 College Road East, Suite 3100, Princeton, New Jersey 08540, (609) 750-8200

---

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, \$0.01 par value

---

(Title of each class of securities covered by this Form)

None

---

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the  
duty to file reports:

Rule           

Rule

Edgar Filing: CYTOGEN CORP - Form 15-12G

12g-4(a)(1)(i)*		12h-3(b)(1)(i)	
Rule	£	Rule	£
12g-4(a)(1)(ii)		12h-3(b)(1)(ii)	
Rule	£	Rule	£
12g-4(a)(2)(i)		12h-3(b)(2)(i)	
Rule	£	Rule	£
12g-4(a)(2)(ii)		12h-3(b)(2)(ii)	
		Rule 15d-6	£

\* The registrant is relying upon current Rule 12g-4(a)(1) to terminate the duty to file reports.

Approximate number of holders of record as of the certification or notice date:\*\* One

\*\*All of the shares of Common Stock, \$0.01 par value, of the registrant were purchased by EUSA Pharma, Inc., in connection with the merger of EUSA Pharma (USA), Inc, a wholly-owned subsidiary of EUSA Pharma, Inc., with and into the registrant, which became effective as of May 8, 2008.

Pursuant to the requirements of the Securities Exchange Act of 1934 Cytogen Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.\*\*

Date: May 9, 2008

By: /s/ KEVIN G. LOKAY

Name: Kevin G. Lokay

Title: President and Chief Executive Officer

Persons who respond to the collection of information contained  
in this form are not required to respond unless the form displays  
SEC 2069 (12-04) a currently valid OMB control number.